[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":97},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100511921","destiny-breast-respond-her2-ultralow-europe-100511921",false,"NCT05945732","DESTINY Breast Respond HER2-(Ultra)Low Europe","A Prospective, Non-interventional Study (NIS) With Trastuzumab Deruxtecan For Patients With HER2-(Ultra)Low Expressing Unresectable and\u002For Metastatic Breast Cancer Accompanied By a Disease Registry of Patients Treated With Conventional Chemotherapy (DESTINY Breast Respond HER2-(Ultra)Low Europe)","Inclusion Criteria:\n\nStudy Group 1 and Study Group 2\n\n* Adult patient (age ≥ 18 years) with histological or cytological confirmed diagnosis of unresectable and\u002For mBC\n* Decision to newly initiate therapy of T-DXd or conventional chemotherapy according to the physicians choice per SmPC\n* Written and signed Informed Consent to participate in the study\n\nStudy Group 1\n\n* Documented HER2-low status (IHC1+, IHC2+\u002FISH-)\n* Patients who have received prior chemotherapy in the metastatic setting or\n* Patients who have developed disease recurrence during or within 6 months of completing adjuvant chemotherapy\n\nStudy Group 2:\n\n* Documented HR+ status\n* Documented HER2-low status (IHC1+ or IHC2+\u002FISH-) or HER2-ultralow (defined as IHC 0 with membrane staining \\[IHC \\> 0 to \\\u003C1+\\]) status\n* Patients who have received at least one endocrine therapy in the metastatic setting\n* Patients who have NOT received prior chemotherapy in the metastatic setting\n\nExclusion Criteria:\n\nStudy Group 1 and Study Group 2\n\n* Pregnancy or breastfeeding\n* Patients who at time of data collection for this study are participating in or have participated in an interventional study that remains blinded.\n\nNo other specific exclusion criteria are defined, as patients will be treated according to the proposed indication statements in the SmPC.","ALL","18 Years",{"count":19,"type":20},2295,"ESTIMATED","OBSERVATIONAL","Trastuzumab deruxtecan (T-DXd) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.\n\nBased on the extended therapeutic indication of Trastuzumab deruxtecan (Enhertu®), a new patient population will be enrolled, comprising adult patients with unresectable or metastatic HR-positive, HER2-low, or HER2-(ultra)low breast cancer who have received at least one endocrine therapy in the metastatic setting and are not considered suitable for endocrine therapy as the next line of treatment.",[24,25,26,27],"Unresectable Breast Cancer","Metastatic Breast Cancer","HER2-low Expressing Breast Cancer","HER2-(Ultra)Low Expressing Breast Cancer",[24,25,26,29,30,31],"Trastuzumab Deruxtecan","Enhertu®","HER2-(ultra)low Expressing Breast Cancer","RECRUITING","2026-06-24",{"date":35,"type":36},"2026-06-29","ACTUAL",{"date":38,"type":36},"2023-10-24",{"date":40,"type":20},"2030-12-31",{"name":42,"class":43},"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","INDUSTRY",211,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100568852","a-study-of-bempedoic-acid-in-combination-with-ezetimibe-and-either-rosuvastatin-or-atorvastatin-in-patients-with-primary-hypercholesterolemia-or-mixed-dyslipidemia-100568852","NCT06686615","A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia","Effectiveness and Safety of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia: an Observational Study","TRICONOS","Key Inclusion Criteria:\n\n1. Written informed consent to participate\n2. At least 18 years of age\n3. High and very high risk patients as assessed by the physician suffering from documented primary hypercholesterolemia or mixed dyslipidemia at start of bempedoic acid treatment\n4. Patients treated with:\n\n   * bempedoic acid added to ezetimibe and rosuvastatin or atorvastatin,\n   * bempedoic acid plus ezetimibe added to rosuvastatin or atorvastatin,\n   * bempedoic acid plus atorvastatin or rosuvastatin added to ezetimibe\n   * initiation of bempedoic acid, ezetimibe, and atorvastatin or rosuvastatin simultaneously\n\n6\\) Initiation of triple therapy within a maximum of four weeks prior to inclusion 7) An untreated LDL-C value must be available within 5 years prior to the start of the triple therapy. Untreated means that the LDL-C value is not influenced by any lipid lowering therapy at the time of blood collection. Time window for not being treated as specified in the protocol.\n\n8\\) No contraindications exist according to the SmPC of bempedoic acid, the respective statin and ezetimibe as per physicians' assessment 9) No concurrent participation in an interventional study (simultaneous participation in other non-interventional studies is possible) 10) Life expectancy \\> 1 -year\n\nKey Exclusion Criteria:\n\n1. Patients who have received PCSK9i monoclonal antibody treatment in the last 3 months before the start of the triple therapy exposure\n2. Patients who have ever received PCSK9i-siRNA treatment",{"count":54,"type":20},2000,"Data on the real-world use and effectiveness and safety of bempedoic acid combined with both a statin and ezetimibe in clinical practice is limited. There is an increased focus on using combination therapy to lower LDL-C.",[57,58],"Primary Hypercholesterolemiia","Mixed Dyslipidemia",[60,61],"Primary hypercholesterolemia","Mixed dyslipidemia","2026-06-09",{"date":64,"type":36},"2026-06-11",{"date":66,"type":36},"2025-02-12",{"date":68,"type":20},"2028-01-31",{"name":42,"class":43},163,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":80,"studyType":21,"phases":4,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},"100515571","a-study-of-trastuzumab-deruxtecan-for-patients-with-advanced-her2-positive-gastric-or-gastroesophageal-junction-adenocarcinoma-who-have-received-a-prior-trastuzumab-based-regimen-accompanied-by-a-disease-registry-of-patients-treated-with-conventional-therapies-prosperity-100515571","NCT05993234","A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)","A Prospective Non-interventional Study (NIS) of Trastuzumab DeRuxtecan (T-DXd) for Adult Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction (GEJ) AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen, Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies in a Real-world Setting in Europe (PROSPERITY)","Inclusion Criteria:\n\n* Male or female adult patient (age ≥ 18 years) with HER2 + advanced gastric or GEJ adenocarcinoma who have received a prior trastuzumab based regimen\n* Histological or cytological confirmed diagnosis of advanced HER2 positive gastric cancer or GEJ\n* Documented HER2 + status (archival sample or recent sample prior 2L therapy)\n* Decision to newly initiate monotherapy T-DXd or conventional therapies per SMPC according to the physician's choice\n* Written dated and signed Informed Consent (ICF) to participate in the study\n\nExclusion Criteria:\n\n* Patients who at time of data collection for this study are participating in or have participated in an interventional study that remains blinded\n* Pregnancy or breastfeeding\n\nNo specific exclusion criteria are defined, as patients will be treated according to the proposed indication statements in the SmPC.",{"count":79,"type":20},257,"2 Years","Trastuzumab deruxtecan (T-DXD) as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.\n\nThis study will assess the effectiveness of T-DXd, patient demographic and clinical characteristics, and treatment patterns in patients with advanced HER2-positive advanced gastric or GEJ adenocarcinoma.",[83,84],"HER2-positive Advanced Gastric Cancer","HER2-positive Gastroesophageal Junction Adenocarcinoma",[83,84,29,86,87],"Conventional therapy","ENHERTU®","2026-05-05",{"date":90,"type":36},"2026-05-08",{"date":92,"type":36},"2023-12-05",{"date":94,"type":20},"2027-09-01",{"name":42,"class":43},76,""]